This company has been marked as potentially delisted and may not be actively trading.

Vapotherm (VAPO) Competitors

VAPO vs. DXR, NSPR, COCH, LUNG, and ECOR

Should you be buying Vapotherm stock or one of its competitors? The main competitors of Vapotherm include Daxor (DXR), InspireMD (NSPR), Envoy Medical (COCH), Pulmonx (LUNG), and electroCore (ECOR). These companies are all part of the "medical equipment" industry.

How does Vapotherm compare to Daxor?

Vapotherm (NYSE:VAPO) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

: Daxor has a net margin of 0.00% compared to Vapotherm's net margin of -76.74%.
Company Net Margins Return on Equity Return on Assets
Vapotherm -76.74% N/A -68.08%
Daxor N/A N/A N/A
: 43.1% of Vapotherm shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 15.8% of Vapotherm shares are owned by insiders. Comparatively, 59.5% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vapotherm
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Daxor
0 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.50
: In the previous week, Daxor had 1 more articles in the media than Vapotherm. MarketBeat recorded 1 mentions for Daxor and 0 mentions for Vapotherm. Vapotherm's average media sentiment score of 0.55 beat Daxor's score of 0.00 indicating that Vapotherm is being referred to more favorably in the media.
Company Overall Sentiment
Vapotherm Positive
Daxor Neutral
: Daxor has lower revenue, but higher earnings than Vapotherm.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vapotherm $68.67M 0.20 -$58.19M -$8.51 N/A
Daxor N/A N/A N/A N/A N/A
: Vapotherm has a beta of -1.11, meaning that its stock price is 211% less volatile than the S&P 500. Comparatively, Daxor has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Vapotherm	-76.74%	N/A	-68.08%
Daxor	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vapotherm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Overall Sentiment
Vapotherm	Positive
Daxor	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vapotherm	$68.67M	0.20	-$58.19M	-$8.51	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Summary

Daxor beats Vapotherm on 7 of the 10 factors compared between the two stocks.

How does Vapotherm compare to InspireMD?

Vapotherm (NYSE:VAPO) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

: Vapotherm has a beta of -1.11, meaning that its stock price is 211% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
: Vapotherm has a net margin of -76.74% compared to InspireMD's net margin of -413.96%. Vapotherm's return on equity of 0.00% beat InspireMD's return on equity.
Company Net Margins Return on Equity Return on Assets
Vapotherm -76.74% N/A -68.08%
InspireMD -413.96% -69.42% -57.68%
: InspireMD has lower revenue, but higher earnings than Vapotherm. InspireMD is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vapotherm $68.67M 0.20 -$58.19M -$8.51 N/A
InspireMD $10.85M 5.01 -$19.92M -$0.73 N/A
: In the previous week, InspireMD had 11 more articles in the media than Vapotherm. MarketBeat recorded 11 mentions for InspireMD and 0 mentions for Vapotherm. Vapotherm's average media sentiment score of 0.55 beat InspireMD's score of 0.22 indicating that Vapotherm is being referred to more favorably in the media.
Company Overall Sentiment
Vapotherm Positive
InspireMD Neutral
: InspireMD has a consensus target price of $4.50, suggesting a potential upside of 287.93%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Vapotherm.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vapotherm
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
InspireMD
0 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
3.00
: 43.1% of Vapotherm shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 15.8% of Vapotherm shares are owned by company insiders. Comparatively, 34.1% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Vapotherm	-76.74%	N/A	-68.08%
InspireMD	-413.96%	-69.42%	-57.68%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vapotherm	$68.67M	0.20	-$58.19M	-$8.51	N/A
InspireMD	$10.85M	5.01	-$19.92M	-$0.73	N/A

Company	Overall Sentiment
Vapotherm	Positive
InspireMD	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vapotherm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

InspireMD beats Vapotherm on 11 of the 16 factors compared between the two stocks.

How does Vapotherm compare to Envoy Medical?

Envoy Medical (NASDAQ:COCH) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

: Vapotherm has a net margin of -76.74% compared to Envoy Medical's net margin of -9,857.26%.
Company Net Margins Return on Equity Return on Assets
Envoy Medical -9,857.26% N/A -256.65%
Vapotherm -76.74% N/A -68.08%
: Envoy Medical has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, Vapotherm has a beta of -1.11, meaning that its stock price is 211% less volatile than the S&P 500.
: Envoy Medical has higher earnings, but lower revenue than Vapotherm. Envoy Medical is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Envoy Medical $240K 211.42 -$23.76M -$1.22 N/A
Vapotherm $68.67M 0.20 -$58.19M -$8.51 N/A
: In the previous week, Envoy Medical had 1 more articles in the media than Vapotherm. MarketBeat recorded 1 mentions for Envoy Medical and 0 mentions for Vapotherm. Vapotherm's average media sentiment score of 0.55 beat Envoy Medical's score of 0.00 indicating that Vapotherm is being referred to more favorably in the news media.
Company Overall Sentiment
Envoy Medical Neutral
Vapotherm Positive
: 8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 43.1% of Vapotherm shares are owned by institutional investors. 7.1% of Envoy Medical shares are owned by insiders. Comparatively, 15.8% of Vapotherm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Envoy Medical currently has a consensus target price of $6.00, suggesting a potential upside of 809.09%. Given Envoy Medical's stronger consensus rating and higher possible upside, research analysts clearly believe Envoy Medical is more favorable than Vapotherm.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Envoy Medical
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
Vapotherm
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-9,857.26%	N/A	-256.65%
Vapotherm	-76.74%	N/A	-68.08%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240K	211.42	-$23.76M	-$1.22	N/A
Vapotherm	$68.67M	0.20	-$58.19M	-$8.51	N/A

Company	Overall Sentiment
Envoy Medical	Neutral
Vapotherm	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Vapotherm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Envoy Medical beats Vapotherm on 8 of the 15 factors compared between the two stocks.

How does Vapotherm compare to Pulmonx?

Vapotherm (NYSE:VAPO) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

: Pulmonx has higher revenue and earnings than Vapotherm. Pulmonx is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vapotherm $68.67M 0.20 -$58.19M -$8.51 N/A
Pulmonx $90.50M 0.59 -$54M -$1.30 N/A
: Vapotherm has a beta of -1.11, meaning that its share price is 211% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.
: Pulmonx has a net margin of -60.09% compared to Vapotherm's net margin of -76.74%. Vapotherm's return on equity of 0.00% beat Pulmonx's return on equity.
Company Net Margins Return on Equity Return on Assets
Vapotherm -76.74% N/A -68.08%
Pulmonx -60.09% -92.94% -39.80%
: Pulmonx has a consensus target price of $5.38, suggesting a potential upside of 323.51%. Given Pulmonx's stronger consensus rating and higher probable upside, analysts clearly believe Pulmonx is more favorable than Vapotherm.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vapotherm
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Pulmonx
1 Sell rating(s)

3 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.38
: In the previous week, Pulmonx had 4 more articles in the media than Vapotherm. MarketBeat recorded 4 mentions for Pulmonx and 0 mentions for Vapotherm. Vapotherm's average media sentiment score of 0.55 beat Pulmonx's score of 0.03 indicating that Vapotherm is being referred to more favorably in the media.
Company Overall Sentiment
Vapotherm Positive
Pulmonx Neutral
: 43.1% of Vapotherm shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 15.8% of Vapotherm shares are held by company insiders. Comparatively, 6.8% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vapotherm	$68.67M	0.20	-$58.19M	-$8.51	N/A
Pulmonx	$90.50M	0.59	-$54M	-$1.30	N/A

Company	Net Margins	Return on Equity	Return on Assets
Vapotherm	-76.74%	N/A	-68.08%
Pulmonx	-60.09%	-92.94%	-39.80%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vapotherm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pulmonx	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Company	Overall Sentiment
Vapotherm	Positive
Pulmonx	Neutral

Summary

Pulmonx beats Vapotherm on 12 of the 16 factors compared between the two stocks.

How does Vapotherm compare to electroCore?

Vapotherm (NYSE:VAPO) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

: 43.1% of Vapotherm shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 15.8% of Vapotherm shares are held by company insiders. Comparatively, 13.8% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: electroCore has a net margin of -44.08% compared to Vapotherm's net margin of -76.74%. Vapotherm's return on equity of 0.00% beat electroCore's return on equity.
Company Net Margins Return on Equity Return on Assets
Vapotherm -76.74% N/A -68.08%
electroCore -44.08% -1,956.38% -80.18%
: In the previous week, electroCore had 6 more articles in the media than Vapotherm. MarketBeat recorded 6 mentions for electroCore and 0 mentions for Vapotherm. Vapotherm's average media sentiment score of 0.55 beat electroCore's score of 0.44 indicating that Vapotherm is being referred to more favorably in the media.
Company Overall Sentiment
Vapotherm Positive
electroCore Neutral
: Vapotherm has a beta of -1.11, suggesting that its stock price is 211% less volatile than the S&P 500. Comparatively, electroCore has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
: electroCore has a consensus price target of $18.00, indicating a potential upside of 187.08%. Given electroCore's stronger consensus rating and higher probable upside, analysts clearly believe electroCore is more favorable than Vapotherm.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vapotherm
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
electroCore
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: electroCore has lower revenue, but higher earnings than Vapotherm. electroCore is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vapotherm $68.67M 0.20 -$58.19M -$8.51 N/A
electroCore $32.03M 1.58 -$13.97M -$1.65 N/A

Company	Net Margins	Return on Equity	Return on Assets
Vapotherm	-76.74%	N/A	-68.08%
electroCore	-44.08%	-1,956.38%	-80.18%

Company	Overall Sentiment
Vapotherm	Positive
electroCore	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vapotherm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vapotherm	$68.67M	0.20	-$58.19M	-$8.51	N/A
electroCore	$32.03M	1.58	-$13.97M	-$1.65	N/A

Summary

electroCore beats Vapotherm on 9 of the 16 factors compared between the two stocks.

Get Vapotherm News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VAPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VAPO vs. The Competition

Export

Metric	Vapotherm	Surgical & medical instruments Industry	Medical Sector	NYSE Exchange
Market Cap	$13.58M	$47.77M	$6.31B	$23.24B
Dividend Yield	N/A	1.08%	2.78%	4.00%
P/E Ratio	-0.25	15.87	28.45	28.31
Price / Sales	0.20	30.28	531.38	23.81
Price / Cash	N/A	18.88	43.30	25.49
Price / Book	-0.24	14.53	9.83	4.67
Net Income	-$58.19M	-$20.10M	$3.55B	$1.07B

Vapotherm Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VAPO Vapotherm	N/A	$2.17 flat	N/A	N/A	$13.58M	$68.67M	N/A	290	High Trading Volume
DXR Daxor	2.0475 of 5 stars	$10.91 +2.4%	N/A	+28.8%	$53.66M	N/A	N/A	37	Gap Up
NSPR InspireMD	3.113 of 5 stars	$1.18 +3.5%	$5.00 +323.7%	-54.6%	$53.46M	$8.98M	N/A	50	Analyst Forecast
COCH Envoy Medical	2.2298 of 5 stars	$0.68 +0.5%	$6.00 +782.4%	-56.4%	$52.03M	$240K	N/A	34
LUNG Pulmonx	2.2547 of 5 stars	$1.28 +6.7%	$5.38 +320.2%	-65.5%	$50.69M	$90.50M	N/A	250	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:VAPO) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vapotherm (VAPO) Competitors